DAWN ResultsRaul Nogueira, MD, analyzes implications from the DAWN trial, where clinical core mismatch patients benefited from thrombectomy up to 24 hours, but chances for good outcomes declined over time.

The Effect of Rivaroxaban with Aspirin on Stroke Outcomes in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) TrialMukul Sharma | Population Health Research Institute, McMaster University, Hamilton, ON, Canada